Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Neoplasms
  • Xenograft Model Antitumor Assays

abstract

  • It is estimated that the development of a new anticancer agent costs US$800 million to 1 billion and takes more than a decade between conception and approval. However, 90% of novel antineoplastic drugs fail in the clinic despite evidence of antitumor efficacy in classical preclinical models. This raises serious concerns as to whether such models are predictive of drug efficacy in humans, particularly in the current era of new targeted therapies, and supports the development of alternative approaches. © 2008 American Society for Clinical Pharmacology and Therapeutics.

publication date

  • February 2009

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1038/clpt.2008.200

PubMed ID

  • 19005462

Additional Document Info

start page

  • 217

end page

  • 21

volume

  • 85

number

  • 2